Alphabet's Isomorphic Labs is in talks to raise roughly $5 billion in new funding to expand its use of artificial intelligence in drug discovery, according to people familiar with the matter.
Reported talks · Alphabet / Isomorphic Labs
Isomorphic Labs is reportedly in talks to raise about $5 billion for AI drug discovery
The reported round would fund a broader push to use AI in the search for new medicines. The details are not independently confirmed, and size, timing, and terms could still change.
~$5B
Reported size of the new funding round (unconfirmed)
Talks
Status described as ongoing, not a closed deal
Years
Typical timeline for traditional drug discovery
The reported round, to scale
Each block = $1 billion. Five blocks represent the roughly $5 billion reported.
Reported round
Scale reference
From reported talks to outcomes
Talks reported, terms unconfirmed
→
Round closes, size and investors set
→
Funds drive research programs
→
Clinical trials and regulators decide
Why it matters
A round this size would be among the larger financings tied to AI drug discovery.
It signals Alphabet extending its AI capabilities further into life sciences.
AI may shorten early-stage research by predicting molecular behavior.
What to watch
AI-driven gains are difficult to verify at scale.
Every candidate must still pass rigorous clinical trials.
Specific programs and milestones have not been publicly detailed.
Bottom line
Large capital can fund longer, costlier research, but approved therapies depend on science and regulators over the coming years.
Continue reading The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in ✓ Signed in — this article isn’t included in your current plan.Unlocking the full article...